Results 31 to 40 of about 8,937 (172)

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

British Journal of Haematology, EarlyView.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile, Vanessa Innao, Salvatrice Mancuso, Enrica Antonia Martino, Antonio Mosca, Giovanna Motta, Francesca Pedalino, Marco Rossi, Fabio Stagno, Giorgio Tona, Francesco Di Raimondo, Giuseppe Alberto Palumbo   +21 more
wiley   +1 more source

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

Haematologica, 2019
The aim of this study was to investigate long-term outcome following first-line therapy in consecutive chronic lymphocytic leukemia (CLL) patients in a well-defined geographic area: Sweden.
Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson, Jenny Klintman, Jenny Bjellvi, Staffan Tolvgård, Eva Kimby, Stefan Norin, Per-Ola Andersson, Claes Karlsson, Karin Karlsson, Birgitta Lauri, Mattias Mattsson, Anna Bergendahl Sandstedt, Maria Strandberg, Anders Österborg, Lotta Hansson   +16 more
doaj   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision‐Making

European Journal of Haematology, EarlyView.
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi, Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +15 more
wiley   +1 more source

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update

Internal Medicine Journal, EarlyView.
Abstract In 2023, a consensus statement on the diagnosis and management of chronic lymphocytic leukaemia (CLL) in Australasia was published. Since then, advances in clinical evidence and increased availability of molecular diagnostics and targeted therapies have further influenced contemporary CLL management.
Sean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, Rory Bennett, Giles Best, Nicole Chia, Tara Cochrane, Kyle Crassini, Gavin Cull, Pietro Di Ciaccio, Pasquale Fedele, Rosemary Harrup, Sharon Jackson, Bryone Kuss, Masa Lasica, Denise Lee, Thomas Lew, Paula Marlton, Monique Menzies Wojtowicz, Stephen Opat, Sumita Ratnasingam, John Francis Seymour, Dipti Talaulikar, Constantine Si Lun Tam, Robert Weinkove, Joel Wight, Stephen Mulligan, Mary Ann Anderson   +27 more
wiley   +1 more source

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region

Frontiers in Oncology, 2020
Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl) associated with rituximab (R) in fludarabine-ineligible patients with treated and untreated chronic lymphocytic leukemia (CLL).
Francesco Autore, Idanna Innocenti, Francesco Corrente, Maria Ilaria Del Principe, Serena Rosati, Paolo Falcucci, Alberto Fresa, Esmeralda Conte, Maria Assunta Limongiello, Daniela Renzi, Laura De Padua, Alessandro Andriani, Francesco Pisani, Giuseppe Cimino, Agostino Tafuri, Marco Montanaro, Francesca Romana Mauro, Giovanni Del Poeta, Luca Laurenti, Luca Laurenti   +19 more
doaj   +1 more source

Survival outcomes in dogs treated with vinorelbine‐based adjuvant treatment following surgical resection of grade II and III pulmonary carcinoma

Journal of Small Animal Practice, EarlyView.
Objectives Pulmonary carcinoma in dogs is commonly managed with surgical resection; however, the role of adjuvant chemotherapy for grade II and III carcinomas remains unclear. This retrospective multicentre study investigated the outcomes in dogs treated with vinorelbine‐based adjuvant treatment (as monotherapy or combined chemotherapy) following ...
N. Wong, L. Brockley, S. Rajan, J. Yu
wiley   +1 more source

Hybrid inhibitors of DNA and HDACs remarkably enhance cytotoxicity in leukaemia cells

Journal of Enzyme Inhibition and Medicinal Chemistry, 2020
Chlorambucil is a nitrogen mustard-based DNA alkylating drug, which is widely used as a front-line treatment of chronic lymphocytic leukaemia (CLL). Despite its widespread application and success for the initial treatment of leukaemia, a majority of ...
Yoojin Song, Sun You Park, Zhexue Wu, Kwang-Hyeon Liu, Young Ho Seo   +4 more
doaj   +1 more source

Codocytosis in the Dog: 345 Cases (2020–2022)

Veterinary Clinical Pathology, EarlyView.
ABSTRACT Introduction Codocytes, or target cells, are a morphologic variation of erythrocytes characterized by increased membrane surface area relative to volume. In dogs, codocytosis is frequently noted on blood smear evaluation, but its clinical significance remains poorly understood. Objectives To characterize the clinical conditions associated with
Sarena M. Krojanker, Maria Jaramillo, Brad D. Cingolani, Floyd L. Williams Jr., Priscila B. S. Serpa, Andrew D. Woolcock   +5 more
wiley   +1 more source

Primary Peritoneal Perivesical Hemangiosarcoma in 16 Dogs (2020–2024)

Veterinary Medicine and Science, Volume 12, Issue 5, September 2026.
Primary peritoneal perivesical hemangiosarcoma in dogs may represent a distinct anatomical presentation of visceral hemangiosarcoma. Despite a high metastatic rate and guarded prognosis, multimodal treatment combining surgery and chemotherapy significantly improved progression‐free and disease‐specific survival compared with chemotherapy alone ...
Jose Roca, Xavier Escoda, Miguel García‐de la Virgen, Ignasi Rodríguez   +3 more
wiley   +1 more source